prothrombin complex concentrate octaplex maude latulippe, ccfp-em res grand rounds, fmc
TRANSCRIPT
![Page 1: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/1.jpg)
Prothrombin complex concentrateOctaplex
Maude Latulippe, CCFP-EM res
Grand Rounds, FMC
![Page 2: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/2.jpg)
CASE
• 73 year old male
• Hx CVA in 2007 and A fib on Coumadin
• Brought in by EMS for right sided weakness and aphasia.
• Pt unable to walk
![Page 3: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/3.jpg)
• Pt speaks limited English and follows a few commands. No family is present.
On exam:
• Vitals 37.2, 100, 16, 167/98, 98% RA
• Glucometer 6.8
• Eyes open spontaneously. He has a right lower face, arm and leg hemiparesis. He is agitated.
• EKG: a fib
• Remainder of physical exam is non-contributory.
![Page 4: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/4.jpg)
PMHX: • Ischemic CVA in 2007
secondary to A fib and subtherapeutic INR. Was left MCA symptomatology
• A fib• CHF• Remote MI• HTN• PVD• Chronic venous insufficiency• Dyslipidemia
Meds: • Warfarin• Lipitor• Micardis• Ramipril• Lasix
![Page 5: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/5.jpg)
![Page 6: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/6.jpg)
Post CT the patient deteriorates: GCS drops to 7 (E2 M4 V1)
Breathing becomes more shallow and appears less effective.
Eyes deviate to the left.
CBC, lytes, creat unremarkable
INR 3.6
PTT N
![Page 7: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/7.jpg)
Management:
• Should vitamin K be given?
• How long does FFP take to work?
• What are the other disadvantages of FFP?
• What new blood product is the best treatment for this patient?
• What are the other indications for Octaplex- prothrombin complex concentrate?
![Page 8: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/8.jpg)
Objectives
• What is Prothrombin Complex Concentrate (PCC)?
• Potential risk
• Advantages: PCC vs Vit K
PCC vs FFP
• How to use it? Indications/Protocol
![Page 9: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/9.jpg)
• Contains FII, (FVII), FIX, FX, and anticoagulant proteins C, S and heparin
• Low volume (average 40cc)• Administered rapidly, quick
onset of action• No need for matching blood
group• Room temperature• Prepared using viral inactivation
method• 1150$ per dose
PROTHROMBIN COMPLEX CONCENTRATE
![Page 10: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/10.jpg)
Octaplex: Contains FII, FVII, FIX, FX in the ratio of approx. 1:1:1:1
![Page 11: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/11.jpg)
Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature, Cindy A. Leissinger, Am. J. Hematol. 83:137–143, 2008
• Review of 14 studies involving urgent warfarin reversal with PCCs
• 460 patients• 7 thrombotic complications =
1.5%• … in patient with a pre pro-
thrombotic co-morbidity
![Page 12: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/12.jpg)
Journal of Thrombosis and Haemostasis, 2008Single-arm prospective study was from Oct 05 to Nov 06 at 15 centers
in Austria, Germany, Hungary, Israel, Lithuania, the Netherlands, Poland, andSwitzerland.
43 patients with INR > 2 : 26 requiring interventional procedures17 acute bleeding
![Page 13: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/13.jpg)
Method:
• Vit K given prior to PCC infusion (88% pt)• Dose Beriplex by INR
• Concomitant tx with blood, plasma hold for 30 min
Primary end point: - INR at 30 min
INR Dose IU/kg2-3.9 254-6 35>6 50
![Page 14: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/14.jpg)
40/43 INR<1.33/43 INR=1.4
![Page 15: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/15.jpg)
Plasma levels of coagulation factors and clotting inhibitors following administration of Beriplex® P/N. F, factor.
![Page 16: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/16.jpg)
![Page 17: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/17.jpg)
Adverse events
• Adverse events in 25 pt (58%)
• Serious : 6 patients– 3 died
1 death possibly related to treatment
• All other serious/non-serious AE not related to treatment
![Page 18: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/18.jpg)
Thromboembolism riskBetter balance pro/anticoag
factor
No active phospholipid
No activated factor (FVIIa, FIXa)
Often only 1 dose required
Viral transmission
4 cases Parvovirus B19 seroconversions
Allergic reaction
New generation PCC
![Page 19: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/19.jpg)
Treatment options for reversal of oral anticoagulants
Vitamin KApplication of vitamin K:
oral: slow decrease of INR, start within 12-24 h
i.v. : slow decrease of INR, start within 6-8 h
FIX and FX takes longer
Warfarin resistance for 1 week
![Page 20: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/20.jpg)
Studies comparing PCC with Vit K
![Page 21: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/21.jpg)
Treatment, time and INR
![Page 22: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/22.jpg)
Fresh frozen plasma (FFP)
• 15 ml/kg – 1050 ml in 70 kg patient• 30-45 min from demand to start infusion• Blood group specific• Thawed• 1-3h for reversal• Longer time to infuse• TRALI, infection, allergic reaction• 200$/unit
![Page 23: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/23.jpg)
Studies comparing PCC and FFP
![Page 24: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/24.jpg)
Hematoma Growth and Outcome in Treated Neurocritical Care Patients With Intracerebral Hemorrhage Related to Oral Anticoagulant TherapyComparison of Acute Treatment Strategies Using Vitamin K, Fresh Frozen Plasma, and Prothrombin Complex Concentrates. Huttner Stroke 2006
• Retrospective review 55 pts ICH-Group 1 (31pts): PCC +- FFP +- VitK-Group 2 (18pts): FFP +- VitK-Group 3 (6pts) VitK• Outcomes-Reversal of INR-Hematoma growth (CT or MRI>33%)-Neurological outcome (1 year)
![Page 25: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/25.jpg)
• INR reversal (<2h)
-84% vs 39% vs 0% (p<0.01)
• Frequency of hematoma growth
-19.3% vs 33.3% vs 50% (p<0.01)
• Extent of hematoma growth
-44% vs 54% vs 59% (NS)
• Incidence of growth PCC vs No PCC
-19.3% vs 37.5% (p<0.01)
• No difference in outcome
![Page 26: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/26.jpg)
PCC vs FFP
Favouring PCC
Rapid
No thawing
No blood group testing and matching
No volume limitation
fast application
Highly predictable effect (Antagonism of OAC)
No acute lung injury (TRALI)
![Page 27: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/27.jpg)
Is INR a good test?
• Sensitive to FII, FVII and X
(but not FIX)
• Thromboelastography a better test?
Profile of clot formation in whole blood
![Page 28: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/28.jpg)
Guidelines controversies
![Page 29: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/29.jpg)
1) For Warfarin reversal only in cases of
Urgent surgical procedure required
or
Massive bleeding – CNS, GI
2) INR >1.5
Indications for use (AHR)
![Page 30: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/30.jpg)
CONTRAINDICATION:A. History HIT
Not recommended for*A. Elective reversal of OAT pre-invasive procedureB. Tx of elevated INRs without bleed or need for surgical
interventionC. Massive transfusionD. Coagulopathy associated with liver dysfonctionE. Recent Hx thrombosis, MI, recent ischemic stroke or
DIC
Special population: Pregnant/lactating women, pediatric, congenital factor II and X deficient patients
*Evaluation case-by-case basis possible with hematologist/transfusion medicine physician on call
![Page 31: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/31.jpg)
PCC Dosage (Regional guidelines):(less than the manufacturer’s recommended dose)
- 40mL (1000IU Factor IX activity) and Vit K 10mg IV(Higher dose may be needed in extremes of INR or weight)
- Max 120mL (3000 IU)
Administration: Initial rate 1mL/min x 10 min max rate 3 mL/min
F-U: PT/INR 15 min post dose
![Page 32: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/32.jpg)
Availability
• Octaplex available at FMC, PLC and RGH
• Any physicians who follow the protocol can order Octaplex.
• An Octaplex request form must be completed and faxed to the transfusion Medicine department.
• Octaplex available very rapidly
![Page 33: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/33.jpg)
Progress of case:
• FFP is ordered. 10mg IV Vitamin K given.
• Transfusion medicine is called to release Octaplex from the blood bank.
• Octaplex 40cc (2 vials) given
![Page 34: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/34.jpg)
• INR is reversed from 3.8 to 1.3 within 15 minutes of administration of Octaplex.
• The patient does not appear to worsen clinically and does not require intubation.
• He is admitted to the Stroke Team. A CT scan the next day unfortunately shows significant progression of the bleed. The patient has very poor neurological function. Goals of care are changed to comfort measures and he dies on the 10th day after admission.
![Page 35: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/35.jpg)
Take home point • Octaplex is a Prothrombin Complex
Concentrate available in Calgary through blood bank
• Contains FII, FVII, FIX, FX, protein C, protein S and heparin
• Use if INR>1.5 + Massive bleeding (GI/ICH)or Urgent surgical procedure needed
• C-I: HIT• Give 2 vials (40cc) + vit K 10 mg IV• Should be effective in less then 30 min, recheck INR• Very sick patients with poor outcomes,
mortality/morbidity benefit still unproven
![Page 36: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/36.jpg)
Special thanks
• Thanks to Dr Carey, Dr Dorrington, Dr Shelagh Coutts (neuro) and Dr Rad (hemato)
• Thanks to Carolyn Jursa, Octapharma representant and to the department of blood product FMC
![Page 37: Prothrombin complex concentrate Octaplex Maude Latulippe, CCFP-EM res Grand Rounds, FMC](https://reader030.vdocument.in/reader030/viewer/2022032706/56649de35503460f94ad9d4b/html5/thumbnails/37.jpg)
• Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital, David Bruce,Tim JC Nokes, Department of Haematology, Derriford Hospital, UK, critical care,2008
• Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial., PABINGER, B. BRENNER J, Thromb Haemost 2008,
• Warfarin-reversal: results of a phase III study with pasteurised, nanofiltrated prothrombin complex concentrate, Ingrid Pabinger-Fasching , Medical University of Vienna, Austria
• Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature, Cindy A. Leissinger, Philip M. Blatt, American Journal of Hematology, 2008
• Current Practices and Unresolved Questions Intracerebral Hemorrhage Associated With Oral Anticoagulant Therapy, Steiner, Stroke 2006
• Hematoma Growth and Outcome in Treated Neurocritical Care Patients With Intracerebral Hemorrhage Related to Oral Anticoagulant Therapy Comparison of Acute Treatment Strategies Using Vitamin K, Fresh Frozen Plasma, and Prothrombin Complex Concentrates, Huttner, Stroke 2006
• The use of PCC in Intensive Care Medicine, symposium Oct 2009, UK• Up to date